I-Mab Reports 83% Response in Givastomig Gastric Cancer Phase 1b

I-Mab has reported highly promising Phase 1b clinical trial results for givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, demonstrating an objective response rate (ORR) of 83% at selected doses when combined with nivolumab and mFOLFOX6 chemotherapy. The study enrolled treatment-naïve patients with metastatic gastric, esophageal, or gastroesophageal adenocarcinomas and showed efficacy across a wide range of PD-L1 and Claudin 18.2 expression levels, with a disease control rate of 100% and durable responses lasting up to 13.3 months. Givastomig was well tolerated, with minimal high-grade adverse events and no dose-limiting toxicities reported up to 18 mg/kg, underscoring its favorable safety profile. These results reinforce givastomig's potential as a best-in-class therapy for gastric cancers with limited existing targeted treatment options, prompting ongoing dose expansion studies and further clinical development. Despite strong clinical data, I-Mab faces financial challenges impacting its stock valuation, although recent positive results have contributed to a significant surge in its market value. The company plans to share additional data in upcoming investor events and scientific congresses, highlighting its commitment to advancing givastomig in the oncology treatment landscape.